NURIX THERAPEUTICS, INC. (NRIX) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 103.78M; Formula and calculation Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-05-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 103.78M | Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-06-30. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 103.78M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-05-31 | 103.78M | (m) | (m) |
| 2026-02-28 | 103.41M | (m) | (m) |
| 2025-08-31 | 76.88M | (m) | (m) |
| 2025-05-31 | 76.45M | (m) | (m) |
| 2025-02-28 | 76.24M | (m) | (m) |
| 2024-08-31 | 70.84M | (m) | (m) |
| 2024-05-31 | 64.41M | (m) | (m) |
| 2024-02-29 | 49.15M | (m) | (m) |
| 2023-11-30 | 48.89M | (m) | (m) |
| 2023-08-31 | 48.50M | (m) | (m) |
| 2023-05-31 | 48.20M | (m) | (m) |
| 2023-02-28 | 47.45M | (m) | (m) |
| 2022-11-30 | 47.27M | (m) | (m) |
| 2022-08-31 | 47.15M | (m) | (m) |
| 2022-05-31 | 47.04M | (m) | (m) |
| 2022-02-28 | 44.95M | (m) | (m) |
| 2021-08-31 | 44.61M | (m) | (m) |
| 2021-05-31 | 44.43M | (m) | (m) |
| 2021-02-28 | 44.35M | (m) | (m) |
| 2020-11-30 | 38.91M | (m) | (m) |
| 2020-08-31 | 38.86M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |